Soluble CD59 in peritoneal dialysis: a potential biomarker for peritoneal membrane function.

Area of Science:

• Nephrology
• Immunology
• Biomarker Discovery

Background:

• Complement regulators are crucial for preventing mesothelial damage during peritoneal dialysis (PD).
• Assessing complement regulators in PD is challenging due to limited access to the peritoneal membrane.
• Soluble CD59 (sCD59), a complement regulatory protein, has recently been identified.

Purpose of the Study:

• To investigate the role of soluble CD59 (sCD59) in peritoneal dialysis (PD).
• To explore sCD59 as a potential biomarker for predicting peritoneal membrane function and residual renal function loss in PD patients.

Main Methods:

• Plasma sCD59 was measured using ELISA in 48 PD patients, 41 hemodialysis patients, 15 chronic kidney disease patients, and 14 healthy controls.
• sCD59 and sC5b-9 were assessed in peritoneal dialysate.
• Patient outcomes, including peritoneal membrane failure and loss of residual renal function, were monitored during follow-up.

Main Results:

• Plasma sCD59 levels were significantly higher in PD patients compared to chronic kidney disease patients and healthy controls.
• Increased sCD59 levels in both dialysate and plasma were independently associated with peritoneal membrane failure.
• Higher plasma sCD59 levels correlated with a greater loss of residual renal function.

Conclusions:

• Soluble CD59 (sCD59) shows potential as a predictive biomarker for peritoneal membrane function in PD.
• sCD59 may also serve as a biomarker for predicting the loss of residual renal function in PD patients.
• These findings suggest sCD59 could be a valuable tool for enhancing patient management in PD.